- 
MRNA most of the people are familiar with the vaccine stocks from pandemic fiasco.
- This company is beaten down to the ground and has low market cap as compared to other biopharma stocks.
- 2025 would be easier for merger and acquisition which will be good for moderna as it might get acquired by other biopharma companies to accelerate their growth.
- Bird Flu in the US and rise of HPMV in China will create an upward pressure in terms of demand of these stocks. Monitor the news for HPMV as it seems it is more severe than the COVID
MRNA most of the people are familiar with the vaccine stocks from pandemic fiasco. - This company is beaten down to the ground and has low market cap as compared to other biopharma stocks.
- 2025 would be easier for merger and acquisition which will be good for moderna as it might get acquired by other biopharma companies to accelerate their growth.
- Bird Flu in the US and rise of HPMV in China will create an upward pressure in terms of demand of these stocks. Monitor the news for HPMV as it seems it is more severe than the COVID
거래청산: 스탑 닿음
closed after gap down
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.
면책사항
해당 정보와 게시물은 금융, 투자, 트레이딩 또는 기타 유형의 조언이나 권장 사항으로 간주되지 않으며, 트레이딩뷰에서 제공하거나 보증하는 것이 아닙니다. 자세한 내용은 이용 약관을 참조하세요.